Abstract
High-dose chemotherapy (HDT), together with autologous stem cell transplantation (ASCT), plays an important role in the treatment of diffuse large B cell lymphoma (DLBCL), especially as second-line therapy. However, its significance in up-front settings remains to be elucidated. In our institute, patients with DLBCL in both the high-intermediate and high international prognostic index (IPI) groups initially underwent CHOP/R-CHOP treatment followed by HDT/ASCT at upfront settings between 2002 and 2011. We retrospectively analyzed 25 patients who were all treated with upfront HDT/ASCT. We excluded one patient who failed to undergo transplantation because of primary refractory disease from the analysis. The median follow-up was 77 months (range 17-110 months). Five-year overall survival (OS) and progression-free survival (PFS) were 91.7 and 79.2 %, respectively, which were higher than the equivalents in previous studies. The OS and PFS in the high-risk group were lower than those in the high-intermediate group. Treatment-related mortalities or fatal complication were not observed. Our results confirm that HDT/ASCT for high-risk aggressive lymphoma is a feasible and promising therapy, but patients with high IPI continued to have po...Continue Reading
References
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W MillsA H Goldstone
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A ShippB Coiffier
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C HaiounF Reyes
May 9, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R M JoyceD Avigan
Mar 27, 2004·The New England Journal of Medicine·Noel MilpiedUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang
Aug 24, 2006·International Journal of Hematology·Li-na HanTakaaki Chou
Nov 16, 2006·Blood·Laurie H SehnJoseph M Connors
Apr 3, 2007·Cancer Treatment Reviews·Alexander GrebAndreas Engert
Nov 1, 2007·Blood·Edo VellengaPeter C Huijgens
Feb 7, 2008·The Cochrane Database of Systematic Reviews·A GrebA Engert
Oct 29, 2008·Blood·Emmanuel GyanUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS)
Jan 16, 2009·Internal Medicine·Kimihito C KawabataShinichi Oka
Jul 10, 2009·Haematologica·Umberto VitoloUNKNOWN Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL)
Mar 18, 2010·Hematological Oncology·Nozomi NiitsuMasataka Okamoto
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marita ZiepertMarkus Loeffler
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corrado TarellaAlessandro Rambaldi
Jan 13, 2011·British Journal of Haematology·Brian T HillJohn Sweetenham
Oct 19, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolas MounierUNKNOWN Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT)
Oct 23, 2012·International Journal of Hematology·Mark RoschewskiWyndham H Wilson
Nov 22, 2012·The Lancet Oncology·Norbert SchmitzUNKNOWN German High-Grade Lymphoma Study Group (DSHNHL)
Dec 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N KettererC Haioun
Citations
Mar 18, 2015·International Journal of Hematology·Daisuke KuritaMasami Takei
Oct 13, 2015·Blood Research·Hong Ghi LeeKeon Woo Park
Mar 6, 2018·Medicine·Zhan ShiXi Tang
Oct 27, 2017·Oncotarget·Ying ZhaoDe-Pei Wu
Aug 28, 2020·Leukemia & Lymphoma·Yoshiaki ChinenUNKNOWN Kyoto Clinical Hematology Study Group investigators
May 17, 2017·Scientific Reports·Jiang XiaoHongxin Zhao
Nov 18, 2020·International Journal of Clinical Practice·Nur Adila AnuarGin Gin Gan
Aug 6, 2019·Acta Haematologica·Xi-Yuan ZhangChun-Lei Shi